Rhubarb and Angiotensin Converting Enzyme Inhibitor

NCT ID: NCT00672451

Last Updated: 2018-12-13

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-01-31
• Study Completion Date: 2009-05-31

Brief Summary

Rhubarb extract is a chinese herbal preparation that is used in china and other asian countries to treat constipation and chronic kidney disease. Use of angiotensin converting enzyme inhibitors (ACEI) in diabetic kidney disease has been shown to be beneficial in slowing progression. The purpose of this study is to determine the combined effect of rhubarb plus enalapril (an ACEI)in slowing the rate of decline of CKD in people with kidney disease from diabetes.

Detailed Description

Use of angiotensin converting enzyme inhibitors (ACEI) in diabetic nephropathy has been shown to be beneficial in slowing progression of disease. This would include use of ACEI, aggressive blood pressure and blood sugar control as well as other possible interventions. Experimental studies in chronic kidney disease (CKD) patients in China has suggested that rhubarb extract when used alone is equivalent to the protection afforded by ACEI. Furthermore when used in combination with ACEI, the renoprotective effect of rhubarb appears to be additive.

Rhubarb extract is a chinese herbal preparation that is used extensively in china and other asian countries to treat constipation and CKD. Its mechanism of action in preventing progression of CKD is uncertain but perhaps related to TGF beta and TNF alpha inhibition.

The specific aim is to determine the combined effect of rhubarb plus enalapril slowing the rate of decline of CKD (using Iothalamate GFRs) in patients in diabetes. A secondary aim would be to measure serum TGF beta concentrations over time and see if any observed decrease in the rate of decline of CKD is related to changes in TGF beta levels.

Conditions

Diabetic Kidney Disease

Keywords

diabetic kidney disease; albuminuria

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

rhubarb extract

will receive rhubarb extract

Group Type: EXPERIMENTAL

rhubarb extract

Intervention Type: DIETARY_SUPPLEMENT

titrate rhubarb extract titrated up to 6grams daily by mouth

placebo

receive placebo

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: DIETARY_SUPPLEMENT

placebo titrated up to 6 pills daily as patient tolerates

Interventions

rhubarb extract

titrate rhubarb extract titrated up to 6grams daily by mouth

Intervention Type: DIETARY_SUPPLEMENT

placebo

placebo titrated up to 6 pills daily as patient tolerates

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

1. Male or female patients >18 years

2. Patients with diabetic nephropathy (history of type 1 or type 2 diabetes for > 7 years, no other cause for proteinuria listed in their medical chart). This is the definition used in most peer-reviewed trials44,45 of diabetic nephropathy. We do recognize that their proteinuria could be due to some other concomitant kidney disease but the only way to confirm that is to do a kidney biopsy which is not clinically justified.

3. Proteinuria ≥ 0.5 g/day

4. Ability to sign consent form

Exclusion Criteria

1. Pre study GFR (see section 10.7) < 20 ml/min

2. Renal disease of etiologies other than diabetes

3. Uncontrolled hypertension (Systolic BP >180 mmHg and Diastolic BP >110mm Hg)

4. Patients with history of kidney stones in past 10 years

5. Patients with active chronic liver disease (Liver enzymes ALT, AST >2.5 times normal)

6. Patients with primary small bowel disease with malabsorption, blind loop syndrome, or jejunoileal bypass surgery (may cause unabsorbed fatty acids to combine with calcium which in turn causes too much absorption of oxalate)

7. Patients with current alcohol, illicit drug use or any other condition (eg. Psychiatry disorder) that in the opinion of the investigator may interfere with the patient's ability to comply with the study

8. Pregnant women or women of child bearing potential who are unwilling to use an adequate form of contraceptive during the course of the study (ACEI may be fetotoxic)

9. Patients with significant unstable cardiovascular disease (NYHA class III and IV)

10. Patients with active malignancy

11. Uncontrolled infections.

12. Patients with a known sensitivity to the study medications (including enalapril)

13. Patients on angiotensin II receptor blockers (ARBs)

14. Microscopic or macroscopic hematuria (to rule out kidney disease other than diabetic nephropathy)

15. Patients on any herbal supplements unwilling to discontinue them

16. Severe malnutrition (serum albumin <2.6mg/dL)

17. Hyperkalemia at baseline, defined as serum potassium ≥ 5.5 mg/dL

18. Iodine allergy.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Center for Complementary and Integrative Health (NCCIH)

NIH

Sponsor Role: collaborator

Wake Forest University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

John Burkart, MD

Role: PRINCIPAL_INVESTIGATOR

Wake Forest University Health Sciences

Locations

Wake Forest University Heath Sciences

Winston-Salem, North Carolina, United States

Countries

United States

Other Identifiers

1R21AT002367-01A2

Identifier Type: NIH

Identifier Source: secondary_id

View Link

IRB00000616

Identifier Type: -

Identifier Source: org_study_id